

Effect of acupoint catgut embedding in chronic fatigue syndrome patients

A protocol for systematic review and meta-analysis

Mei-Lin Zhang, MB^a , Hong-Juan Fu, MD^{b,c}, Yong Tang, MM^{a,*}, Zhen-Guo Luo^a, Jian-Yong Li^a, Rui Li^a

Abstract

Background: Chronic fatigue syndrome (CFS) is a relatively complex and disabling illness with a substantial economic burden and functional impairment. Until now, many CFS patients lack appropriate healthcare. Acupoint catgut embedding is an effective and emerging alternative therapy for CFE. With this research, we endeavor to investigate the effect and safety of ACE for CFS.

Methods: Eight databases will be searched from inception to December 2020: PubMed, EMBASE, The Cochrane Library, Web of Science, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, Chong-Qing VIP database, and Wanfang database. We regard studies as eligible for inclusion if they were RCTs done in CFS patients, compare acupoint catgut embedding to another treatment strategy, and report fatigue changes at the end of the intervention period. Two independent reviewers complete the study selection, data extraction, and the risk of bias assessment. We assess pooled data using a random-effects model through Revman software (v.5.3) and Stata (version 15.0).

Ethics and dissemination: Ethics approval is not required because the individual patient data will not be involved, with no privacy concerns. This systematic review and meta-analysis will provide a reference for CFS patients and clinicians on the non-drug interventions. We will publish and disseminate the results of this review in a peer-reviewed journal or relevant conference.

OSF Registration number: 10.17605/OSF.IO/7SHD9 (<https://osf.io/7shd9>).

Abbreviations: CBM = Chinese Biomedical Literature Database, CFS = Chronic Fatigue Syndrome, CI = confidence interval, CNKI = Chinese National Knowledge Infrastructure, MD = mean difference, PRISMA-P = Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols, RCTs = randomized controlled trials, RevMan = Review Manager Software, RR = risk ratio, SMD = standard mean difference, VIP = the Chongqing VIP Chinese Science and Technology Periodical Database.

Keywords: acupoint catgut embedding, chronic fatigue syndrome, meta-analysis, protocol, systematic review

Private information from participants will not be made public, and their rights will not be compromised in this review. Therefore, there is no need for ethical approval. The results may be disseminated in a peer-reviewed journal or relevant conferences.

This work is supported by a grant from the research on the application of massage techniques based on PFPD pelvic floor rehabilitation equipment (No. zjxx-2020-04).

The sponsors have no role in design, conducting or revising the study protocol.

The authors have no conflicts of interest to disclose.

^a Acupuncture-moxibustion School of Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, ^b School of Acupuncture-moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, ^c Sichuan Integrative Medicine Hospital, Chengdu, Sichuan, China.

* Correspondence: Yong Tang, Acupuncture-moxibustion School of Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, No. 6, Xinchuang Road, High-tech West District, Chengdu 610097, Sichuan, China (e-mail: 529545233@qq.com).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Zhang ML, Fu HJ, Tang Y, Luo ZG, Li JY, Li R. Effect of acupoint catgut embedding in chronic fatigue syndrome patients: a protocol for systematic review and meta-analysis. *Medicine* 2021;100:5(e23946).

Received: 28 November 2020 / Accepted: 1 December 2020

<http://dx.doi.org/10.1097/MD.00000000000023946>

1. Introduction

Chronic fatigue syndrome (CFS) is a severe, debilitating condition that affects millions of people worldwide,^[1] causing profound, prolonged illness and disability.^[2–4] CFS is characterized by medically unexplained fatigue that persists for more than 6 months and comprises a range of symptoms, fluctuating in intensity and severity. Patients with CFS are more functionally impaired than those with other disabling illnesses, such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, congestive heart failure, and other chronic conditions.^[2] It has been reported that at least one-quarter of CFS patients are at home or bed-ridden at some point in their lives,^[5] imposing an enormous burden for patients, their caregivers, the health care system, and society, with an estimated direct and indirect economic cost of \$18 to \$24 billion annually.^[6–10] The 3 most prevalent causes of death in CFS patients were heart failure, suicide, and cancer.^[11] CFS patients mean age of death is considerably younger than those who died from cancer and suicide in the general population.^[12]

Although researchers pay substantial efforts to understand CFS better, diagnosing the disease is still a challenge because patients often struggle with their illness for years before an identification is made.^[1,2] Due to CFS diagnosis uncertainties and a lack of clinical guidance for clinicians, many patients do not receive appropriate healthcare.^[6] Research into CFS focus on treatment or management

increasing only in recent years. At present, cognitive-behavioral therapy (CBT) is known as one commonly used in treating CFS, with evidence supporting its effectiveness and cost-effectiveness.^[13,14] However, it may be argued that currently there is no comprehensive agreement on what counts as “CBT”.^[15] To further improve effectiveness, researchers advocate investigating multidisciplinary treatments, including CBT in combination with other interventions, such as complementary alternative therapies.^[16]

Acupoint catgut embedding (ACE) in traditional Chinese medicine (TCM) is an alternative treatment and comes to the attention of researchers.^[17] ACE involves the implantation of absorbable sutures at traditional Chinese meridian acupoints, with the dual effects of acupuncture and suture absorption stimulation.^[18] ACE is a combination product of ancient traditional acupuncture and modern tissue therapy,^[19] which can conserve time and costs compared to other alternative therapies.^[20,21] Currently, CFSs etiology involves various factors, including immunological, genetic, viral, neuroendocrine and psychological, especially being closely related to immunity and inflammation.^[22] This technique is supposed to be beneficial to relieve fatigue in CFS patients.^[23–25] Previous researches conformed that ACE exhibits analgesic effects,^[19,20,26] improves immune system function,^[23] and mitigates inflammation and oxidative stress.^[27] Besides, Yang^[28] founded that the effect of ACE for CFS is similar to ginsenoside. Therefore, acupoint catgut embedding has the potential to be a useful supplementary treatment option for chronic fatigue syndrome. However, ACEs effect on CFS is still controversial based on the current evidence-based medical evidence. Therefore, the present works chief aim is to obtain a relatively convincing conclusion of whether acupoint catgut embedding is useful for alleviating fatigue in patients with chronic fatigue syndrome.

2. Methods

2.1. Study registration

This protocol strictly follows the PRISMA-P guidelines^[29] with an Open Science Frame-work registration number 10.17605/OSF.IO/7SHD9 (<https://osf.io/7shd9>).

2.2. Eligibility criteria

2.2.1. Types of studies. RCTs investigating the effect of acupoint catgut embedding (ACE) on relieving fatigue in CFS patients will be included.

2.2.2. Types of participants. Participants diagnosed with CFS by either of the following diagnostic criteria will be included: Fukuda Case Definition for CFS (1994),^[30] Canadian Consensus

Criteria for ME/CFS (2003), NICE Clinical Guidelines for CFS/ME (2007),^[2] Revised Canadian Consensus Criteria for ME/CFS (2010), International Consensus Criteria for ME (2011),^[31] and The Institute of Medicine (2015).^[1]

2.2.3. Types of interventions. Intervention measure is ACE, regardless of intervention duration, frequency, acupoint, and absorbable suture types. ACE and adjunct therapy combination treatment will be included.

2.2.4. Types of comparators. The comparison groups involve another treatment strategy, such as cognitive-behavioral therapy (CBT), acupuncture, moxibustion, or sham ACE.

2.2.5. Types of outcome measures. The primary outcome is fatigue outcomes scale: Fatigue Scale-14 (FS-14), Brief Fatigue Inventory (BFI), Fatigue Severity Scale (FSS), Checklist Individual Strength (CIS), and Fatigue Impact Scale (FIS). The secondary outcomes are quality of life, pain, insomnia, anxiety, and other clinical outcomes.

2.3. Search methods for identification of studies

2.3.1. Information sources. Two researchers (YT and ZGL) independently select relevant studies published from inception to December 1, 2020 by searching PubMed, Embase, Web of Science, The Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, the Chongqing VIP Chinese Science and Technology Periodical Database (VIP), Chinese Biomedical Literature Database (CBM), and Clinical-Trials.gov. We apply no language restrictions. Besides, we will manually search the reference list of critical articles to find potential studies.

2.3.2. Search. We use the following combined text and MeSH terms: acupoint catgut embedding, catgut embedding, chronic fatigue syndrome, fatigue syndrome. An example of the search strategy for PubMed is in Table 1.

2.4. Data collection and analysis

2.4.1. Study selection. Two independent investigators (YT, JYL) will import search results into EndNote X8 (Bld 10063) and then remove duplicate articles. They review titles and abstracts to remove irrelevant literature, non-RCTs, animal experiments, case reports, and systematic reviews. Studies that satisfy the inclusion criteria will be retrieved for full-text assessment. The exclusion reasons will be recorded in an excel table. Disagreements will be resolved by a third reviewer (MLZ). The study selection process of this review will be presented in Figure 1.

Table 1

Search strategy for PubMed.

#1	“acupoint catgut embedding” [Title/Abstract] OR “catgut embedding” [Title/Abstract] OR “catgut” [Title/Abstract]
#2	“Chronic Fatigue Syndrome” [MeSH Terms]
#3	“Chronic Fatigue Syndrome” [Title/Abstract] OR “fatigue” [Title/Abstract] OR “tired” [Title/Abstract] OR “weariness” [Title/Abstract] OR “weakness” [Title/Abstract] OR “asthenia” [Title/Abstract]
#4	#2 OR #3
#5	“Clinical Trials as Topic” [MeSH Terms]
#6	“Randomized Controlled Trials as Topic” [MeSH Terms]
#7	“randomized controlled trial” [Title/Abstract] OR “clinical trial” [Title/Abstract] OR “clinical study” [Title/Abstract] OR “randomized trial” [Title/Abstract] OR “controlled trial” [Title/Abstract]
#8	#5 OR #6 OR #7
#9	#1 AND #4 AND #8




Figure 1. Flow chart of the study.

2.4.2. Data extraction. Two reviewers (ZGL, RL) independently extract the following data from each eligible study: the first author, year of publication, country of origin, number of participants, age, sex, diagnostic criteria, intervention duration, frequency, acupoints, absorbable suture types, changes in outcomes, adverse events at the end of the intervention. We will cross-check all data and transfer it into Review Manager (version 5.3, Cochrane Library) and Stata (version 15.0). Any disagreements will be arbitrated by a third reviewer (MLZ).

2.4.3. Assessment of risk of bias. We apply The Cochrane Collaborations tool for assessing the risk of bias (RoB) in included RCTs according to the following 7 aspects: random sequence generation, allocation concealment, participant blinding, analyst blinding, data completeness of results, selective reports, and other sources of bias. Disagreements will be resolved by a third reviewer (MLZ).

2.4.4. Summary measures. We will make a meta-analysis when the number of eligible studies was more than one in each outcome. We calculate the standardized mean difference

(SMD) with a 95% confidence interval (CI) and select a random-effect model to pool data. For categorical outcomes, we calculate pooled estimates of the relative risk with a random-effects model. The Review Manager (version 5.3, Cochrane Library) and Stata (version 15.0) will be applied for statistical analyses.

2.4.5. Unit of analysis issues. This review will not involve individual patient data. Different units of the outcome will be converted to international units before analysis.

2.4.6. Dealing with missing data. The corresponding authors will be contacted by telephone or email to obtain the missing information. We will discuss the potential impact of missing data on the final findings of the review.

2.4.7. Assessment of heterogeneity. This protocol adopts forest plots and I^2 statistics to assess the magnitude of the heterogeneity between studies. I^2 values of 0 implying no heterogeneity; values of 25% mean low heterogeneity; values greater than 50% are supposed to be indicative of moderate-to-

high heterogeneity.^[32] We will explore the sources of heterogeneity when significant heterogeneity was detected.

2.5. Synthesis of results

We option the random-effects model to synthesis the data. The meta-analysis will not be conducted when considerable heterogeneity existed between studies, which is unexplainable, and a narrative summary will be presented.

2.5.1. Risk of bias across studies. We will evaluate the possibility of publication bias by constructing a funnel plot when more than 10 studies are included. We also further assess funnel plot asymmetry using Begg and Egger tests and define significant publication bias as a *P* value <.1. The trim-and-fill computation will be applied for estimating the impact of publication bias on the interpretation of the results.^[33]

2.5.2. Subgroup analysis. We will perform subgroup analyses according to variations in the duration, frequency, and absorbable suture types of ACE when data are available.

2.5.3. Sensitivity analysis. We will conduct a sensitivity analysis to monitor the robustness of the preliminary decision made in the review process. We also further evaluate the impact of a single study on the overall pooled estimate.

2.5.4. Evidence quality evaluation. We will use the Grades of Recommendations Assessment, Development and Evaluation (GRADE) system to evaluate the certainty of merged data. The quality of evidence will be specified to 4 grades: high, moderate, low, and very low quality.^[34]

3. Discussion

Previous researches have demonstrated that acupoint catgut embedding is beneficial for alleviating fatigue in CFS. Due to the small sample of studies, the traditional systematic assessment cannot reach an accurate conclusion on ACE intervention. We designed this protocol based on previous studies to throw light on the nature of ACEs effect and safety for CFS. This systematic review and meta-analysis will provide a relatively convincing conclusion of whether acupoint catgut embedding effectively treats chronic fatigue syndrome patients. Conclusions drawn from this review may benefit patients, clinical practitioners, and policymakers.

Author contributions

Conceptualization: Mei-Lin Zhang.

Data curation: Yong Tang, Zhen-Guo Luo.

Formal analysis: Yong Tang, Jian-Yong Li.

Funding acquisition: Mei-Lin Zhang.

Resources: Mei-Lin Zhang.

Software: Rui Li.

Writing – original draft: Mei-Lin Zhang.

Writing – review & editing: Hong-Juan Fu.

References

[1] Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. *Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness*. Washington (DC): National

Academies Press (US); 2015. PMID: 25695122. DOI: 10.17226/19012.

- [2] National Collaborating Centre for Primary Care (UK). *Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy): Diagnosis and Management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy) in Adults and Children* [Internet]. London: Royal College of General Practitioners (UK); 2007. PMID: 21563329.
- [3] Myalgic encephalomyelitis: international consensus, criteria. *J Intern Med* 2017;282:353doi: 10.1111/joim.12658. Erratum for: *J Intern Med*. 2011 Oct;270(4):327-38. PMID: 28929634; PMCID: PMC6885980.
- [4] Morris G, Puri BK, Walker AJ, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities. *Pharmacol Res* 2019;148:104450.
- [5] Jason LA, Brown A, Evans M, et al. Contrasting chronic fatigue syndrome versus myalgic encephalomyelitis/chronic fatigue syndrome. *Fatigue* 2013;1:168–83.
- [6] Bae J, Lin JS. Healthcare utilization in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): analysis of us ambulatory healthcare data, 2000–2009. *Front Pediatr* 2019;7:185.
- [7] Lin JS, Resch SC, Brimmer DJ, et al. The economic impact of chronic fatigue syndrome in Georgia: direct and indirect costs. *Cost Eff Resour Alloc* 2011;9:1.
- [8] Close S, Marshall-Gradsnik S, Byrnes J, et al. The economic impacts of myalgic encephalomyelitis/chronic fatigue syndrome in an Australian cohort. *Front Public Health* 2020;8:420.
- [9] Pheby DFH, Araja D, Berkis U, et al. The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of Myalgic Encephalomyelitis (ME/CFS): a report from the European Network on ME/CFS (EUROMENE). *Healthcare (Basel)* 2020;8:88.
- [10] Jason LA, Benton MC, Valentine L, et al. The economic impact of ME/CFS: individual and societal costs. *Dyn Med* 2008;7:6.
- [11] McManimen SL, Devendorf AR, Brown AA, et al. Mortality in patients with myalgic encephalomyelitis and chronic fatigue syndrome. *Fatigue* 2016;4:195–207.
- [12] Jason LA, Corradi K, Gress S, et al. Causes of death among patients with chronic fatigue syndrome. *Health Care Women Int* 2006;27:615–26.
- [13] Vos-Vromans D, Evers S, Huijnen I, et al. Economic evaluation of multidisciplinary rehabilitation treatment versus cognitive behavioural therapy for patients with chronic fatigue syndrome: A randomized controlled trial. *PLoS One* 2017;12:e0177260.
- [14] McPhee G. Cognitive behaviour therapy and objective assessments in chronic fatigue syndrome. *J Health Psychol* 2017;22:1181–6.
- [15] Bohman B, Santi A, Andersson G. Cognitive behavioral therapy in practice: therapist perceptions of techniques, outcome measures, practitioner qualifications, and relation to research. *Cogn Behav Ther* 2017;46:391–403.
- [16] Price JR, Mitchell E, Tidy E, et al. Cognitive behaviour therapy for chronic fatigue syndrome in adults. *Cochrane Database Syst Rev* 2008;2008:CD001027.
- [17] Wang T, Xu C, Pan K, et al. Acupuncture and moxibustion for chronic fatigue syndrome in traditional Chinese medicine: a systematic review and meta-analysis. *BMC Complement Altern Med* 2017;17:163.
- [18] Inprasit C, Huang YC, Lin YW. Evidence for acupoint catgut embedding treatment and TRPV1 gene deletion increasing weight control in murine model. *Int J Mol Med* 2020;45:779–92.
- [19] Du K, Wang X, Chi L, et al. Role of Sigma-1 Receptor/p38 MAPK inhibition in acupoint catgut embedding-mediated analgesic effects in complete Freund's adjuvant-induced inflammatory pain. *Anesth Analg* 2017;125:662–9.
- [20] Cui WQ, Sun WS, Xu F, et al. Spinal Serotonin 1A receptor contributes to the analgesia of acupoint catgut embedding by inhibiting phosphorylation of the N-methyl-D-aspartate receptor GluN1 subunit in complete Freund's adjuvant-induced inflammatory pain in rats. *J Pain* 2019;20: 16.e1-16.e16. doi: 10.1016/j.jpain.2018.07.011. Epub 2018 Aug 10. PMID: 30102991.
- [21] Xu F, Xuan LH, Zhou HJ, et al. Acupoint catgut embedding alleviates insomnia in different Chinese medicine syndrome types: a randomized controlled trial. *Chin J Integr Med* 2019;25:543–9.
- [22] Bagnall AM, Whiting P, Richardson R, et al. Interventions for the treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis. *Qual Saf Health Care* 2002;11:284–8.
- [23] Mingfang LYU, Yaqiong LIU, Xiuwu HU, et al. Effect of acupoint catgut embedding combined with mixed moxibustion on chronic fatigue

- syndrome and its influence on immune function of patients. *Medical Innovation of China* 2019;16:81–4.
- [24] Chenyao WANG, Xinying QIU, Jin LIU, et al. Clinical evaluation of special drug acupoint catgut embedding for chronic fatigue syndrome. *Chin Arch Traditi Chin Med* 2018;36:1982–5.
- [25] Wenhai GUO, Zhaoxian LI, Shanshan JIANG, et al. Clinical observation on acupoint catgut implantation combined with medicinal cake moxibustion for chronic fatigue syndrome. *J ClinAcupuncture and Moxibustion* 2016;32:41–3.
- [26] Tang WJ, Wang YQ, Tang B. Effect of acupoint catgut embedding on levels of PG-related factors and NF-(B proteins in ute-rine tissues of rats with primary dysmenorrhea. *Zhen Ci Yan Jiu* 2020;45:548–51.
- [27] Li D, Sun T, Chi L, et al. Acupoint catgut embedding improves the lipopolysaccharide-induced acute respiratory distress syndrome in rats. *Biomed Res Int* 2020;2020:2394734.
- [28] Qizhao YANG. Mechanism Study of Acu-Point Catgut Embedding on Chronic Fatigue Syndrom Rat. China: Master's Thesis: Guangzhou University of Chinese Medicine; 2015.
- [29] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;350:g7647.
- [30] Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. *Ann Intern Med* 1994;121:953–9.
- [31] Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: international consensus criteria. *J Intern Med* 2011;270:327–38.
- [32] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.
- [33] Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455–63.
- [34] Atkins D, Best D, Briss PA, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. *BMJ* 2004;328:1490.